艾尔齐医药公司的阿尔茨海默病药物ACD856在动物身上显示出有前景,改善记忆力和减轻症状,目前正在进入第二阶段试验. AlzeCure Pharma's Alzheimer’s drug ACD856 showed promise in animals, improving memory and reducing symptoms, and is moving toward Phase II trials.

在AD/PD 2026会议上,AlzeCure Pharma分享了其阿尔茨海默病候选药物NeuroRestore ACD856的新临床前结果,显示该化合物以剂量依赖的方式通过Trk受体增强神经质信号传递,改善记忆力并减少动物模型中的抑郁症状. AlzeCure Pharma shared new preclinical results for its Alzheimer’s drug candidate, NeuroRestore ACD856, at the AD/PD 2026 conference, showing the compound enhances neurotrophin signaling via Trk receptors in a dose-dependent way, improving memory and reducing depressive symptoms in animal models. 这些数据支持它有保护脑细胞,减少炎症和改变疾病进展的潜力. The data support its potential to protect brain cells, reduce inflammation, and modify disease progression. 作为一流的候选产品,ACD856正在进入第二阶段试验中, 最近获得了欧洲创新委员会 (European Innovation Council) 的资金. ACD856, a first-in-class candidate, is advancing toward Phase II trials and recently received funding from the European Innovation Council. 该公司正在开发跨平台的多种疗法, 针对神经退行性疾病和慢性疼痛. The company is developing multiple therapies across platforms targeting neurodegenerative diseases and chronic pain.